Co-Diagnostics, Inc.

Co-Diagnostics, Inc. develops and commercializes molecular diagnostic technologies and tests, with a focus on PCR-based platforms used to detect infectious diseases and other targets. The company also appears to support commercialization through licensing, distribution, and related diagnostic product activities rather than a broad consumables or hospital-equipment model.

−7 881,0 %

64,3 %

−7 533,6 %

−84,1 %

3.87

3.59

— Co-Diagnostics, Inc.
%
Molecular diagnostic tests60% PCR and other molecular assays used to detect infectious diseases and other biological targets.
Diagnostic technology platform20% Proprietary CoPrimer technology and related assay design capabilities that underpin test performance.
Licensing and commercialization15% Licensing, distribution, and partner-led commercialization of diagnostic products and technologies.
Other corporate activities5% Ancillary corporate and financing-related activities that support the business.

Customers are primarily laboratories, healthcare providers, distributors, and commercial partners that need molecular...

  • Clinical laboratoriesprimary

    Buy PCR-based assays and test kits to run diagnostic workflows for infectious disease detection.

  • Distributors and channel partnersprimary

    Purchase or license products to commercialize them in local markets where the company lacks direct reach.

  • Healthcare providerssecondary

    Use diagnostic tests to support patient care, triage, and treatment decisions.

  • Commercial licensing partnerssecondary

    License technology or assays to expand product availability and monetize the platform.

  • Public health and screening customersemerging

    Use molecular tests for surveillance, outbreak response, or high-volume screening.

The company is based in the United States, but the available excerpts do not disclose a country-by-country revenue...

  • •Headquartered in the United States
  • •No country-level revenue disclosure was provided in the excerpts
  • •Likely relies on partner-led international commercialization
  • •Regulatory access and local distribution matter for market expansion
  • •Geographic mix cannot be quantified from the provided filings

The company’s strategy appears centered on advancing its molecular diagnostic platform and expanding commercialization...

01
Commercialize diagnostic products through partnersshort-term

Partner-led distribution can extend reach without requiring a large direct-sales footprint.

02
Fund development and expansionshort-term

The company states it expects to use available funds to finance future development and expansion.

03
Strengthen diagnostic platform differentiationmedium-term

Proprietary assay design technology can support product performance and licensing value.

Co-Diagnostics faces the typical risks of a small molecular diagnostics company: commercialization uncertainty,...

high

Commercialization and adoption risk

Revenue depends on customers and partners adopting the company’s molecular tests and technology.

Scope
Test sales, licensing, and channel partnerships
Materiality
high
high

Financing dilution risk

The company has used equity-based financing and advisory-share issuance, which can dilute existing holders.

Scope
Common stock issuance and equity distribution agreements
Materiality
high
high

Regulatory and reimbursement risk

Diagnostic products often require approvals, clearances, and payer acceptance before scaling.

Scope
New assay launches and geographic expansion
Materiality
high
medium

Competitive pressure

The molecular diagnostics market includes larger, better-capitalized competitors with broader menus.

Scope
PCR and infectious disease testing
Materiality
medium
Share-based and equity-settled advisory compensation
Affects operating expenses, dilution, and equity balances
Revenue recognition for diagnostics and licensing
Affects quarterly revenue timing and comparability
Going-concern and liquidity assessment
Affects disclosure, financing assumptions, and valuation

CS DIAGNOSTICS CORP.

CSDX · Specialty Cleaning, Polishing and Sanitation Preparations

Insight Molecular Diagnostics Inc.

IMDX · In Vitro & In Vivo Diagnostic Substances

Cocrystal Pharma, Inc.

COCP · Pharmaceutical Preparations

NEOGENOMICS INC

NEO · Services-Testing Laboratories

Cardio Diagnostics Holdings, Inc.

CDIO · In Vitro & In Vivo Diagnostic Substances

Global Innovative Platforms Inc.

GIPL · Surgical & Medical Instruments & Apparatus

: 28/04/2026